Angiotensin converting enzyme inhibitors: Properties and side effects

Hypertension

Volumn 11, Issue 3, 1988, Pages II.37-II.41

  Gavras, Haralambos ^a,b   Gavras, Irene ^a,b  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme Inhibition; Class effects; Kinetics; Pharmacodynamics; Toxic effects

Indexed keywords

EID: 84929461948     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.hyp.11.3_pt_2.ii37     Document Type: Article

References (78)

1. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-con verting enzyme: new class of orally active antihypertensive agents. Science 1977;196:441-444.
2. Gavras H, Brunner HR, Turini GA, et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978;298:991-995.
3. Patchett AA, Haris E, Tristam EW, et al. A new class of angiotensin converting enzyme inhibitors. Nature 1980;288:280-283.
4. Gavras H, Biollaz J, WaeberB, Brunner HR, Gavras I, Davits RO. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor 'MK-421'. Lancet 1981;2:543-547.
5. Drayer JIM, Weber MA. Monotherapy of essentia] hypertension with a converting enzyme inhibitor. Hypertension 1983; 5(suppl m):III-108-III-113
6. Yodfat Y, Fidel J, Bloom DS. Captopril as a replacement for multiple therapy in hypertension: a controlled study. J Hyper-tens 1985;3(suppl 2):S155-S158
7. Gavras H, Liang C, Brunner HR. Redistribution of regional blood flow after inhibition of the angioten sin-con verting enzyme. Cite Res 1978; 43(suppl I):I-59-I-63
8. Lewis RA, Baker KM, Ayers CR, Weaver BA, Lehman MR. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects. J Cardiovasc Pharmacol 1985; 7(suppl I):512-515
9. Blythe WB. Captopril and renal autoregulation. N Engl J Med 1983;308:390-391.
10. DeVenuto G, Andreorti C, Mattarei M, Pegoretti G. Long-term captopril therapy at low doses reduces albumin excretion in patients with essential hypertension and no sign of renal impairment. J Hypertens 1985;3(suppl I):S143-S145
11. Vidt LXJ, Bravo EL, Fouad FM. Medical intelligence: drug therapy. N Engl J Med 1982;306:214-220.
12. Frohlich ED, Cooper RA, Lewis EJ. Review of the overall experience of captopril in hypertension. Arch [mem Med 1984;144:1441-1444.
13. Hollenberg NK. Angiotensin-Converting enzyme inhibition: renal aspect. J Cardiovasc Pharmacol 1985;7(suppl 1):S40-S44
14. Farrow PR, Wilkinson R. Reversible renal failure during treatment with captopril. Br Med J 1979;1:1680.
15. Collaste P, Haglund K, Lundgren G, Magnussen G, Ostman J. Reversible renal failure during treatment with captopril. Br Med J 1979;2:612-613.
16. Ponce SP, Jennings AE, Madias NE, Harrington JT, Drug-induced hyperkalemia. Medicine (Baltimore) 1985;64:357-370.
17. Davies RO, Irvin JD, Kramsch DK, Walker JF, Moncloa F. Enalapril worldwide experience. Am J Med 1984;77(2A):23-35
18. Jett GK. Captopril-induced angiodema. Ann Emerg Med 1984;13:489-490.
19. Sesoko S, Kaneko Y. Cough associated with the use of Captopril [Utter]. Arch Intern Med 1985;145:1524.
20. Semple PF, Herd GW. Cough and wheeze caused by inhibitor of angiotensin-converting enzyme [Letter]. N Engl J Med 1986;314: 61.
21. Salena BJ. Chronic cough and the use of captopril: unmasking asthma. Arch Intern Med 1986;146:202-203.
22. Al-Mufti HI, Arieff AI. Captopril-induced hyponatremia with irreversible neurologic damage. Am J Med 1985;79:769-771.
23. Packer M, Medina N, Yushak M. Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. Ann Intern Med 1984;100:782-789.
24. Heel RC, Brogden RN, Speight TM, Avery GS. Drugs 1980;20:409-452.
25. Kripalani KJ, McKinistry DN, Singhvi SM, Willard DA, Vu-kovich RA, Migdalof BM. Disposition of Captopril in normal subjects. Clin Pharmacol Ther 1980;27:636-641.
26. Captopril: benefits and risks in severe hypertension [Editorial]. Lancet 1980;2:129-130.
27. Gross DM, Sweet CS, Ulm EH, et al, Effect of N-[(S)-I-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin-converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharmacol Exp Ther 1981;216:552-557.
28. Sweet CS, Gross DM, Arbegast FT, et al. Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421) an orally active converting enzyme inhibitor. J Pharmacol Exp Ther 1981;216:558-566.
29. Reinhardt LA, Wilkin JK, Kirkendall WM. Lichenoid eruption produced by Captopril. Cutis 1983;31:98-99.
30. Aurell M, Delin K, Herlitz H, Mulec H. Captopril treatment in hypertensive dialysis patients, Scand J Urol Nephrol 1982;16:251-256.
31. Chriseler A, Waeber B, Brunner HR, Delacr'etaz J. Superficial pemphigus caused by captopril. Schweiz Med Wochenschr 1982;112:1483-1486.
32. Wilken JK, Kirkendall WM. Pityriasis rosea-like rash from captopril. Arch Dermatol 1982;118:186-187.
33. Solinger AM. Exfoliative dermatitis from captopril. Cutis 1982;29:473-474.
34. Vlasses PH, Rotmensch HH, Ferguson RK, Sheaffer SL. “Scalded mouth“ caused by an gi Mens in-converting enzyme inhibitors. Br Med J (Clin Res) 1982;284:1672-1673.
35. Nicholls MG, Maslowski AH, Ikram H, Espiner EA. Ulceration of the tongue: a complication of captopril therapy. Ann Intern Med 1981;94;659
36. Wizcmann A. Necrotizing blepharitis following captopril-induced agranulocytosis. Klin Monatsbl Augenheilkd 1983;182:82-85.
37. Pennell DJ, Nunan TO, O'Doherty MJ, Croft DN. Fatal Stevens-Johnson syndrome in a patient on captopril and allo-purinol [Letter]. Lancet 1984;1:463.
38. Van Brummelen P, Willemeze R, Tan WD, et al. Captopril-associated agranulocytosis [Letter]. Lancet 1980;1: 150
39. Amman FW, Buhler FR, Conen D, et al. Captopril-associated agranulocytosis [Letter]. Lancet 1980;1:150.
40. Staessen J, Fagard R, Lijnen P, et al. Captopril and agranulocytosis. Lancet 1980;1:926-927.
41. Beroniade V. Side-effects of captopril in advanced chronic kidney insufficiency. Proc Eur Dial Transplant Assoc 1983;20:530-537.
42. Israeli A, Or R, Leitersdorf E. Captopril-associated transient aplastic anemia. Acta Haematol (Basel) 1985;73:106-107.
43. Gavras I, Graff LG, Rose BD, et al. Fatal pancytopenia associated with the use of captopril. Ann Intern Med 1981;94:58-59.
44. Iro H, Henschke F, Konig HJ. Reversible panmyelopathy following captopril treatment. Dtsch Med Wochenschr 1986;111:139-141.
45. Safar ME. Fatal bone-marrow suppression associated with captopril. Br Med J (Clin Res) 1981;283:791-792.
46. el-Makri, Larabi MS, Kechrid C, Belkahia C, Ben Ayed H. Fatal bone-marrow suppression associated with captopril. Br Med J (Clin Res) 1981;283:277-278.
47. Cooper RA, Captopril-associated neutropenia: who is at nsk? Arch Intern Med 1983;143:659-660.
48. Gavras I, Gavras H. Leukopenia: Idiopathic or drug induced [Letter], N Engl J Med 1982;306:484.
49. Studer A, Verier W. Reversible leucopenia associated with angiotensin-con verting enzyme inhibitor MK 421 [Letter], Lancet 1982;1;458
50. Moncloa F, Sromovsky JA, Walker JF, Davies RO. Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety. Drugs 1985;30(suppl I):82-89
51. Hoomtje SJ, Weening JJ, The TH, Kallenberg CGM, Donker JM, Hoedemacher PJ. Immune-complex glomerulopathy in patients treated with captopril. Lancet 1980;1:1212-1215.
52. Textor SC, Gephardt GN, Bravo EL, et al. Membranous glomerulopathy associated with captopril therapy. Am J Med 1983;74:705-712.
53. Fotino S, Spom P. Nonoliguric acute renal failure after captopril therapy. Arch Intern Med 1983;143:1252-1253.
54. Mason JC, Hilton PJ. Reversible renal failure due to captopril in a patient with transplant artery stenosis. Case report. Hypertension 1983;5:623-627.
55. Coulie P, DePlaen JF, van Ypersele de Strihou C. Captopril-induced acute reversible renal failure. Nephron 1983;35:108-111.
56. Steinmann TI, Silva P. Acute renal failure, skin rash, and eosinophilia associated with captopril therapy. Am J Med 1983;75:154-156.
57. Captopril Collaborative Study Group: Does captopril cause renal damage in hypertensive patients? Lancet 1982;1:988-990.
58. WaeberB, Gavras 1, Brunner HR, Gavras H. Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update. J Clin Pharmacol 1981;21:508-515.
59. Rotmensch HH, Vlasses PH, Ferguson RK. Resolution of captopril-induced rash after substitution of enalapril. Pharmacotherapy 1983;3:131-133.
60. Gavras I, Gavras H. Captopril and enalapril. Ann Intern Med 1983;98:556-557.
61. Smith CD, Smith RD, Kom JH. Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor MK 421 (enalapril) in captopril-intolerant patients. Arthritis Rheum 1984;27:826-828.
62. Barnes JN, Davies ES, Gent CB, Rash, eosinophilia, and hyperkalemia associated with enalapril. Lancet 1983;2:41-42.
63. Rahmat J, Gelfand RL, Gelfand MC, Winchester JF, Schreiner GE, Zimmerman HJ. Captopril-associated cholestatic jaundice, Ann Intern Med 1985;102:56-58.
64. Parker WA. Captopril-induced cholestatic jaundice. Drug Intell Clin Pharm 1984;18:234-235.
65. Taillan B, Pedinielli FJ, Blanc AP, Jauffret P, Ferrer JC. Toxic hepatitis caused by captopril [Letter], Therapie 1985;40:263.
66. Sandyk R. Parkinsonism induced by captopril. Clin Neuro-pharmacol 1985;8:197-198.
67. Gillman MA, Sandyk R. Reversal of captopril-induced psychosis with naloxone [Letter]. Am J Psychiatry 1985;142:270.
68. Atkinson AB, Brown JJ, Lever AF, et al. Neurological dysfunction in two patients receiving Captopril and Cimetidine. Lancet 1980;2:36-37.
69. Kallenberg CG, Hoorntje SJ, Smit AJ, et al. Antinuclear and antinative DNA antibodies during Captopril treatment. Acta Med Scand 1982;211:297-300.
70. Patri P, Nigro A, Rebora A. Lupus erythematosus-like eruption from captopril. Acta Derm Vemereol (Stockh) 1985;65:447-448.
71. Smit AJ, Hoomtje SJ, Donker AJ. Zinc deficiency during captopril treatment. Nephron 1983;34:196-197.
72. Cressman MD, Vidt DG, Acker C. Renal glycosuria and azotemia after enalapril maleate (MK-421) [Letter], Lancet 1982;2:440.
73. Gomez HJ, Cirillo VJ, Irvin JD. Enalapril: a review of human pharmacology. Drugs 1985; 30(suppl T): 13-24
74. Pipkin FB, Turner SR, Symonds EM. Possible risk with captopril in pregnancy: some animal data [Letter], Lancet 1980;1:1256
75. Rothberg Ad, Lorenz R. Can captopril cause fetal and neonatal renal failure? Pediatr Pharmacol (New York) 1984;4:189-192.
76. Guignard JP, Burgener F, Calame A. Persistent anuria in a neonate: a side effect of captopril [Letter]? Int J Pediatr Nephrol 1981;2:133.
77. Boutroy MJ, Verl P, Hurault de Ligny B, Milton A. Captopril administration in pregnancy impaired fetal angiotensin converting enzyme activity and neonatal adaptation. Lancet 1984;2:935-936.
78. Mackaness GB. The future of angioten sin-con verting enzyme inhibitors. J Cardiovasc Pharmacol 1985;7(suppl I):S30-S34